MIRIM, Israel, February 8, 2016 /PRNewswire/ —
Via Surgical Ltd., a leading developer of novel surgical fixation technologies for mesh placement in hernia repair, announced today the company has secured a $6M investment led by Benslie investment group.
Nicolas Weinstein, managing partner at Benslie will join the Via Surgical Board of Directors.
Lena Levin, the Company’s Co-founder and CFO, notes: “The addition of Benslie Investment group to our highly experienced team validates the opportunity to advance patient care with the FasTouch™ Deployable Suture Fixation System. Their investment will greatly support the increasing clinical demand for improved fixation through our development and commercialization efforts in 2016.
FasTouch™, a novel fixation technology is the first with the potential to provide a comprehensive fixation solution in hernia repair. The lockable sutures are designed to signficantly minimize foreign body material, providing the first and only light-weight hernia fixation system.”
“We are very excited to partner with Via Surgical to introduce a novel hernia mesh fastening device with the potential to improve patient outcomes. It is a fantastic device that benefits all stakeholders. Via Surgical is a great addition to our portfolio of healthcare companies with a proven team, top advisory board and late stage technology” observed Nicolas Weinstein managing partner at Benslie.
About Via Surgical Ltd.
Via Surgical Ltd. provides next-generation fixation technology. Realizing that many hernia repairs make use of multiple means for mesh fixation – anchor/helical hernia tacks, manually applied transfascial sutures – Via Surgical has developed its FasTouch™ system to provide deployable suture fixation that is strong and consistent, yet easily and rapidly deployed for hernia repair.
Please visit https://www.viasurgical.com for more information.
Benslie investment group is led by Mr. Alejandro Weinstein Manieu. Mr. Weinstein carries extensive industry experience. He transformed a local Chilean pharmaceutical company, CFR Pharmaceuticals, into a global pharmaceutical powerhouse, eventually selling it in 2014. Mr. Weinstein has served as a board member for various pharmaceutical companies in Latin America, Europe, and South East Asia, and of several social initiatives such as Educa UC, Fundación Genomika, and Consorcio Tecnologico en Biomedicina.
Co-Founder and CEO